Floatz logo

Ambrisentan

Metabolic Syndrome X

University of Wisconsin, MadisonSmall moleculePhase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Metabolic Syndrome X cohort.

Asset / SponsorPhaseRating
Topamax
All India Institute of Medical Sciences, Bhubaneswar
Phase 4BBB
Cilnidipine
Boryung Pharmaceutical Co., Ltd
Phase 4BB
TAMOXIFEN
Veterans Medical Research Foundation
Phase 4BB
EXEMESTANE
Veterans Medical Research Foundation
Phase 4BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Korea University Anam Hospital
Phase 4BB

View all 25 →

Same molecule, other indications

Ambrisentan is also rated in:

pulmonary hypertensionDormant
CCC
Indicative ·
53 / 100
View asset →
cirrhosis of liverDormant
CCC
Indicative ·
52 / 100
View asset →
pulmonary hypertensionDormant
CCC
Indicative ·
49 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →